aTyr Pharma (NASDAQ:ATYR – Get Free Report) had its price objective lifted by equities researchers at Wells Fargo & Company from $17.00 to $25.00 in a report released on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price suggests a potential upside of 378.93% from the company’s previous close.
Separately, HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of aTyr Pharma in a research note on Wednesday, June 4th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $20.20.
Check Out Our Latest Analysis on ATYR
aTyr Pharma Stock Up 1.0%
aTyr Pharma (NASDAQ:ATYR – Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.02. As a group, research analysts anticipate that aTyr Pharma will post -0.91 EPS for the current year.
Institutional Trading of aTyr Pharma
Several hedge funds have recently modified their holdings of ATYR. Group One Trading LLC acquired a new position in aTyr Pharma during the fourth quarter worth $26,000. XTX Topco Ltd boosted its position in shares of aTyr Pharma by 74.9% during the 1st quarter. XTX Topco Ltd now owns 19,556 shares of the company’s stock worth $59,000 after purchasing an additional 8,374 shares in the last quarter. OMERS ADMINISTRATION Corp grew its stake in shares of aTyr Pharma by 7.3% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 148,100 shares of the company’s stock worth $447,000 after purchasing an additional 10,100 shares during the period. Victory Capital Management Inc. acquired a new position in shares of aTyr Pharma during the 4th quarter worth $37,000. Finally, Raymond James Financial Inc. purchased a new position in shares of aTyr Pharma in the 4th quarter valued at about $39,000. 61.72% of the stock is owned by institutional investors and hedge funds.
About aTyr Pharma
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Featured Stories
- Five stocks we like better than aTyr Pharma
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- GE Aerospace Turns Engines Into Long-Term Profits
- Consumer Staples Stocks, Explained
- Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes
- What is Insider Trading? What You Can Learn from Insider Trading
- Marvell’s New AI Chip Deals Capture Wall Street’s Attention
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.